{"id":2881,"date":"2026-09-04T22:35:34","date_gmt":"2026-09-04T20:35:34","guid":{"rendered":"https:\/\/peptelia.com\/bpc-157-und-tb-500-2\/"},"modified":"2026-10-12T09:42:33","modified_gmt":"2026-10-12T07:42:33","slug":"bpc-157-and-tb-500","status":"publish","type":"page","link":"https:\/\/peptelia.com\/en\/bpc-157-and-tb-500\/","title":{"rendered":"BPC-157 and TB-500: The Combination in Research Context"},"content":{"rendered":"

BPC-157 and TB-500<\/strong> are named in the same breath remarkably often in peptide research \u2014 and confused with one another just as often. Both are synthetic research peptides, both appear in models of tissue regeneration, yet they originate from entirely different directions and act at different points. This page sets out what lies behind the two molecules, why the literature frequently considers them together, and in which formats they are available as research material at Pept\u00e9lia.<\/p>\n

The two molecules at a glance<\/h2>\n

BPC-157<\/h3>\n

BPC-157 is a synthetic pentadecapeptide \u2014 fifteen amino acids \u2014 whose sequence was derived from a protein described in gastric juice. The abbreviation stands for “Body Protection Compound”. In the preclinical literature it serves as a model substance when processes around tissue integrity and angiogenesis are examined in cell and animal models. BPC-157 is not approved as a medicinal product in any country.<\/p>\n

TB-500<\/h3>\n

TB-500 is the common designation for a synthetic fragment or analogue of the endogenous protein thymosin beta-4. It comprises seven amino acids and is used in research as a tool for investigating cytoskeletal processes \u2014 actin binding in particular \u2014 and cell migration. TB-500 is likewise not an approved medicinal product. A more detailed classification is given in the library entry on TB-500<\/a>.<\/p>\n

Why the literature looks at both together<\/h2>\n

The reason is methodological, not pharmacological. Both peptides appear in the same class of preclinical models \u2014 models in which tissue repair, cell migration and the formation of new blood vessels are studied. Anyone mapping such processes in a model frequently works with several reference substances in parallel in order to keep different points of action distinguishable.<\/p>\n

That is precisely where the substantive difference lies: work on BPC-157 centres mainly on vessel formation and tissue integrity, work on TB-500 on actin dynamics and cell migration. Two different questions that can be examined side by side within the same experimental setup \u2014 hence the frequent joint mention. Statements as to whether the two substances complement, reinforce or influence one another cannot be derived from this literature and are expressly not made here.<\/p>\n

All findings referred to here come from preclinical investigations in cell and animal models. They are described in the preclinical literature and are reported neutrally; these findings do not support conclusions about effects in humans.<\/p>\n

Formats available at Pept\u00e9lia<\/h2>\n

Both peptides are offered individually as a lyophilised powder in a vial, as a capsule formulation and in a combined variant:<\/p>\n